Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, octubre 20
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
CRISPR Therapeutics AG
CRSP
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$49.88
-0.16
-0.32%
Últ. Act.: Oct 20, 4:46 PM
$49.00
-1.04
-2.08%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
CRISPR Therapeutics Financials
CRISPR Therapeutics (CRSP) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Cathie Wood Claps Back After Being Confronted as ARKK Fell Nearly 15% While QQQ Soared 112% in Five Years — Calls It an ‘Incorrect Comparison’
Cathie Wood defends ARKK's 15% drop vs QQQ's 112% 5-year gain, calling it an 'incorrect comparison' and blaming 'endpoint sensitivity.'
Rishabh Mishra
PRO
CRISPR Therapeutics Q2 EPS $(0.94) Beats $(1.17) Estimate, Sales $10.181M Beat $6.789M Estimate
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.17) by 19.66 percent. This is a 60.83 percent increase over losses of $(2.40) per share
Benzinga Newsdesk
PRO
CRISPR Therapeutics Q1 EPS $(1.28) Misses $(1.20) Estimate, Sales $1.458M Miss $2.700M Estimate
Benzinga Newsdesk
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens
CRISPR Therapeutics highlights progress in clinical trials & uptake of Casgevy gene therapy. Pipeline also advancing with promising data.
Vandana Singh
CRISPR Therapeutics Earnings Report: Q4 Overview
Benzinga Insights
PRO
CRISPR Therapeutics Q4 EPS $(1.37) Misses $(1.09) Estimate, Sales $864.000K
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.37) per share which missed the analyst consensus estimate of $(1.09) by 25.92 percent. This is a 211.36 percent decrease over losses of $(0.44) per share
Benzinga Newsdesk
